U.S. flag

Un sitio web oficial del gobierno de Estados Unidos.

Dot gov

La terminación .gov significa que el sitio es oficial.

Los sitios web del gobierno federal con frecuencia terminan en .gov o en .mil. Antes de compartir información delicada, cerciórese de que se encuentra en un sitio del gobierno federal.

Https

Este sitio es seguro.

El protocolo https:// asegura de que se va a conectar al sitio web oficial, y que toda la información que proporcione se cifra y se transmite con seguridad.


VIDEOS ON MONOCLONAL ANTIBODIES
 

Video Icon FEATURED VIDEO

Vaccines and the Role of Monoclonal Antibody Treatment
Dr. Reed Tuckson, founding member of the Black Coalition Against COVID‑19, discusses how clinicians should counsel their patients regarding vaccination and monoclonal antibody treatment.


LEARN MORE ABOUT mAbs

Watch the videos below for tips on counseling your COVID-19 patients about monoclonal antibody treatments.

TREATING HIGH-RISK COVID-19 PATIENTS WITH MONOCLONAL ANTIBODIES

In this video you’ll learn more about monoclonal antibodies, how they can be used to treat your high-risk COVID-19 patients, and how you can find treatment centers near you.


PROVIDER EXPERIENCES

In these short videos, providers from different settings discuss how they have increased patient access to monoclonal antibody treatment.

DR. MARY DITTRICH: ADMINISTERING MONOCLONAL ANTIBODIES TO HIGH-RISK COVID-19 PATIENTS

Dr. Mary Dittrich, Chief Medical Officer for U.S. Renal Care, discusses how she set up infusion centers in dialysis centers to ensure high-risk patients received timely access to monoclonal antibody treatment.

GRAND VIEW AND TRIVALLEY PRIMARY CARE – COMMUNITY COLLABORATION TO ADMINISTER MONOCLONAL ANTIBODIES

Grand View Health pharmacists and primary care physicians from Grand View Medical and TriValley Primary Care discuss how they brokered powerful partnerships in their community to ensure high-risk COVID-19 patients received monoclonal antibody treatment.

DRS. KAREN MURPHY & KEITH BOELL: MONOCLONAL ANTIBODY TREATMENT IN A HEALTH SYSTEM SETTING

Drs. Karen Murphy and Keith Boell discuss their people-first approach to community health and the proactive measures they took to identify and counsel high-risk COVID-19 patients regarding monoclonal antibodies as a treatment option.

DR. TERESE HAMMOND TESTIMONIAL – EQUITABLE ACCESS TO MONOCLONAL ANTIBODY TREATMENT

Dr. Terese Hammond, Program Medical Director at Providence Saint John's Health Center, discusses her efforts to ensure equitable access to monoclonal antibody treatment for high-risk COVID-19 patients across Southern California.

DR. NATALIE MCGANN: MONOCLONAL ANTIBODY TREATMENT IN A PRIMARY PRACTICE SETTING

Dr. Natalie McGann of TriValley Primary Care discusses how they overcame obstacles to administer monoclonal antibody treatments to high-risk COVID patients in a primary practice setting.

DR. GARY M. WILTZ, CEO/CLINICAL CHO, TECHE ACTION CLINIC

Dr. Gary M. Wiltz, CEO/Clinical CHO, Teche Action Clinic, speaks about the challenges of treating COVID-19 patients in rural Southeast Louisiana. Together with local church leaders and TV and radio stations, he is trying to spread the word about the benefits of the monoclonal antibody treatment for high-risk COVID-19 patients.

COLIN QUINN SPEAKS TO DR. JEFFREY BANDER

Stand-up comedian Colin Quinn (Saturday Night Live, Tough Crowd) speaks to Dr. Jeffrey Bander from Mount Sinai Hospital about how monoclonal antibodies helped him recover from COVID-19.

AMY HILL TESTIMONIAL VIDEO

Filmmaker Amy Hill describes her experience with COVID-19 and how monoclonal antibody treatment helped speed up her recovery.


EVENTS

EQUITABLE ACCESS TO MONOCLONAL ANTIBODY TREATMENT: EXAMPLES FROM TWO STATES

Watch Dr. Joneigh Khaldun (Chief Medical Executive for the State of Michigan and Chief Deputy Director for Health in the Michigan Department of Health and Human Services) and Dr. Howard Haft (Executive Director of the Maryland Primary Care Program) discuss their insights on equitable access to monoclonal antibody treatment for high-risk COVID-19 patients in their respective states. Moderated by Ms. Cicely Waters (HHS/ASPR).

WHAT PHYSICIANS NEED TO KNOW ABOUT MONOCLONAL ANTIBODIES

Watch a discussion with Dr. Michael Anderson, senior advisor at the HHS Office of the Assistant Secretary for Preparedness and Response in Washington, D.C., about what physicians need to know about monoclonal antibody treatments and their incredible effectiveness in helping certain patients avoid hospitalization for COVID-19.

PAST EVENT: DISCUSSION OF MONOCLONAL ANTIBODIES

The Facebook Live event featuring Dr. Vin Gupta and former FDA Commissioner Dr. Robert Califf is available for viewing at any time.

For more information, healthcare providers can visit the resources page.

PAST EVENT: NIH “A” RATING FOR mAbs

Watch Dr. H. Clifford Lane (NIH) and Dr. Raj Gandhi (Harvard) discuss the updated recommendations on the use of monoclonal antibodies released by the NIH COVID-19 Treatment Guidelines Panel in April 2021. Moderated by Ms. Cicely Waters (HHS/ASPR.)


Administración de anticuerpos monoclonales en sus instalaciones

Estos videos (en inglés) se ofrecen como recursos para ayudarle a establecer infusiones de anticuerpos monoclonales en sus instalaciones, aprender más sobre el tratamiento con anticuerpos monoclonales e incrementar la concientización sobre sus beneficios.*

Ponentes: Jenny Waltzer, directora de oncología y servicios de infusión terapéutica, Lisa Kimbury, jefe de práctica clínica avanzada, Marisa Marvin y Victoria Adams, farmacéutica clínica de enfermedades infecciosas.


TRATAMIENTO CON ANTICUERPOS MONOCLONALES: FLUJO DE PACIENTES

El primer video de una serie del Hospital Mount Sinai en Nueva York, describe las operaciones y la configuración de los servicios de infusión de anticuerpos monoclonales.

MONOCLONAL ANTIBODY TREATMENT: EDUCATION TRAINING

Third in a series from Mount Sinai Hospital in New York, describing the operations and set up of mAb infusion services. This video addresses the topic of managing education and training.

 

* La referencia en este documento a cualquier producto, proceso o servicio comercial específico por su nombre comercial, marca registrada, fabricante u otro, no constituye necesariamente ni implica su aprobación, recomendación o favorecimiento por parte del Gobierno de los Estados Unidos. Los puntos de vista y las opiniones de los autores expresados en este documento no necesariamente afirman ni reflejan los del gobierno de los Estados Unidos, y no se utilizarán con fines publicitarios o de promoción de productos.